Labor Day may not quite be upon us but forget about the last BBQ party of summer, it's time to don the Christmas sweater and deck the tree because this year's must have holiday season toys list is ...

These are just a few of the things that my five young kids have played with and obsessed over—despite the avalanche of actual toys to choose from in our house. Kids will play with just about ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Marking its 10+ years in the industry, The HOTH shares a collection of client success stories, highlighting the company's impact on businesses across various sectors. St. Petersburg, Florida ...

Amazon released its annual “Toys We Love” list on Sept. 10, previewing its take on the hottest toys of 2024 and of the upcoming holiday shopping season. This year’s 2024 list includes 300 ...

(RTTNews) - Hoth Therapeutics, Inc. (HOTH) Tuesday announced promising preclinical results for its investigational Alzheimer's drug, HT-ALZ. The company's shares were rising more than 15 percent ...

Hoth Therapeutics shares rose on Tuesday after the company said early clinical data of its therapeutic HT-ALZ suggested a potential "breakthrough" in the treatment of Alzheimer's disease. Shares ...

NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced ...

Short interest in Hoth Therapeutics Inc (NASDAQ:HOTH) increased during the last reporting period, rising from 212.46K to 219.36K. This put 3.2% of the company's publicly available shares short.

5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the ...